Preface

Advanced Drug Delivery Reviews

Volumn 87, Issue , 2015, Pages 1-2

  Juliano, R L ^a   Ming, Xin ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL PENETRATING PEPTIDE; EPHRIN RECEPTOR A2; LIPID; LIPOSOME; LONG UNTRANSLATED RNA; MICRORNA; MONOCLONAL ANTIBODY; NANOPARTICLE; OLIGONUCLEOTIDE; SMALL INTERFERING RNA;

BIOTECHNOLOGY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG RESEARCH; DUCHENNE MUSCULAR DYSTROPHY; EDITORIAL; ENDOCYTOSIS; HUMAN; INTRACELLULAR TRANSPORT; OLIGONUCLEOTIDE THERAPY; OVARY CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; DRUG DEVELOPMENT;

BIOTECHNOLOGY; DRUG DISCOVERY; OLIGONUCLEOTIDES;

EID: 84965186408     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.06.010     Document Type: Editorial

References (6)

1. Goodchild J., Agrawal S., Civeira M.P., Sarin P.S., Sun D., Zamecnik P.C. Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:5507-5511.
2. Mello C.C., Conte D. Revealing the world of RNA interference. Nature 2004, 431:338-342.
3. Nat. Biotechnol. 2006, 24:1453.
4. Carroll J. Merck writes off RNAi, punts Sirna to Alnylam for $175M http://www.fiercebiotech.com/story/merck-writes-rnai-punts-sirna-alnylam-175m/2014-01-13.
5. Anon. Will RNAi therapeutics ever succeed? Roche, Pfizer, Abbott, Merck, Novartis trim commitments http://www.proactiveinvestors.com/companies/news/19679/will-rnai-therapeutics-ever-succeed-roche-pfizer-abbott-merck-novartis-trim-commitments-19679.html.
6. Tse M.T. Regulatory watch: antisense approval provides boost to field. Nat. Rev. Drug Discov. 2013, 12:179.